TY - JOUR
T1 - Growth Hormone Safety Workshop Position Paper: a critical appraisal of recombinant human growth hormone therapy in children and adults.
AU - Allen, David B
AU - Backeljauw, Philippe
AU - Bidlingmaier, Martin
AU - Biller, Beverly
AU - Boguszewski, Margaret
AU - Burman, Pia
AU - Butler, Gary
AU - Chihara, K
AU - Christiansen, Jens Sandahl
AU - Cianfarani, Stefano
AU - Clayton, Peter E
AU - Clemmons, David
AU - Cohen, Pinchas
AU - Darendeliler, Feyza
AU - Deal, Cheri
AU - Dunger, David P
AU - Erfurth, Eva Marie
AU - Fuqua, John
AU - Grimberg, Adda
AU - Haymond, Morey
AU - Higham, Claire
AU - Ho, Ken K Y
AU - Hoffman, Andrew R
AU - Hokken-Koelega, Anita Cs
AU - Johannsson, Gudmundur
AU - Juul, Anders
AU - Kopchick, John J
AU - Lee, Peter
AU - Pollak, Michael
AU - Radovick, Sally
AU - Robison, Leslie
AU - Rosenfeld, Ron
AU - Ross, Richard J
AU - Savendahl, Lars
AU - Saenger, Paul
AU - Toft Sorensen, H
AU - Stochholm, Kirstine
AU - Strasburger, Christian J
AU - Swerdlow, Anthony
AU - Thorner, Michael O
PY - 2015
Y1 - 2015
N2 - Recombinant human growth hormone (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety including; cancer risk, impact on glucose homeostasis and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk and the need for longterm surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.
AB - Recombinant human growth hormone (rhGH) has been in use for 30 years, and over that time its safety and efficacy in children and adults has been subject to considerable scrutiny. In 2001, a statement from the GH Research Society (GRS) concluded that 'for approved indications, GH is safe'; however, the statement highlighted a number of areas for on-going surveillance of long-term safety including; cancer risk, impact on glucose homeostasis and use of high dose pharmacological rhGH treatment. Over the intervening years, there have been a number of publications addressing the safety of rhGH with regard to mortality, cancer and cardiovascular risk and the need for longterm surveillance of the increasing number of adults who were treated with rhGH in childhood. Against this backdrop of interest in safety, the European Society of Paediatric Endocrinology (ESPE), the GRS and the Pediatric Endocrine Society (PES) convened a meeting to reappraise the safety of rhGH. The ouput of the meeting is a concise position statement.
U2 - 10.1530/EJE-15-0873
DO - 10.1530/EJE-15-0873
M3 - Article
C2 - 26563978
SN - 1479-683X
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
ER -